Gilead Acquires Arcellx for $7.8 Billion

Arcellx Inc's stock surged 78.13% in pre-market trading, reaching a 52-week high, following Gilead's announcement of its acquisition agreement.

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for $115 per share in cash, totaling $7.8 billion. This acquisition reflects Gilead's confidence in Arcellx's innovative therapies, particularly the potential FDA approval of Anito-cel for multiple myeloma, which is expected to enhance Gilead's market position significantly. The deal is anticipated to close in Q2 2026, with Gilead projecting an increase in earnings per share starting in 2028, driven by the expected success of Anito-cel.

The acquisition is seen as a strategic move for Gilead, solidifying its leadership in oncology and expanding its portfolio in blood cancer treatments. The strong market reaction to the acquisition indicates heightened investor interest in Arcellx, which may lead to further stock price appreciation.